Stan Yakatan
Mr. Stan Yakatan is Chairman and Chief Executive Officer of Katan Associates, a private company which he founded in May 1989 that provides advisory services and strategic planning for companies in the life sciences industry. From June 2003 to August 2005, Mr. Yakatan was Chairman and Chief Executive Officer of Grant Life Sciences, a publicly-traded company engaged in the research, development, marketing, and sale of diagnostic kits for the screening, monitoring, and diagnosis of diseases with emphasis on women's health, infectious diseases, and cancers. Mr. Yakatan continues to serve as a Director of Grant Life Sciences. He is also a Director of several privately-held companies in the life sciences industry. From 1968 until he founded Katan Associates in 1989, Mr. Yakatan held various senior executive positions with New England Nuclear Corporation (a division of E.I. DuPont), ICN Pharmaceuticals, Inc., New Brunswick Scientific Co., Inc. and Biosearch. Mr. Yakatan is the Chairman of Biocomm Inc., a venture capital firm, and has founded and served as Chief Executive Officer of numerous entrepreneurial ventures in the biomedical and healthcare sectors. He has served as a strategic advisor to government agencies in Canada and Australia.

Theodore A. Greenberg
Mr. Greenberg has more than 20 years experience in investment management, consulting, and public accounting.

In 2005, he joined Infinity Capital Group, Inc., a business development company. He currently serves as Chief Investment Officer, Chief Financial Officer, and Secretary, and is a member of Infinity's board. Since 2004 he has been, and continues to be, a project consultant and advisor and has provided services to various companies, including a private equity fund, a children's entertainment company, a real estate development fund, a software development company and an internet company. In 1999, Mr. Greenberg co-founded Park Avenue Equity Partners, LP, a $100 million middle market private equity fund and he was a general partner until 2003. From 1998 to 1999, Mr. Greenberg was the Chief Financial Officer of Development Capital, LLC.

Mr. Greenberg has also held senior positions at various accounting firms. Mr. Greenberg was appointed to the Board in April 2006.

John Lanzafame
Mr. Lanzafame began his tenure with Biophan in 2004 serving as vice president of business development and chief operating officer before being appointed CEO on September 14, 2007.

From 1989 through 2004, Lanzafame held several senior level executive positions at STS Biopolymers, Inc., a company that develops and manufactures proprietary advanced polymer coatings for use on medical devices.  He served as director of operations, vice president of sales and marketing, and president.

STS Biopolymers was acquired by Angiotech Pharmaceuticals during Mr. Lanzafame’s tenure as president.

He earned his Bachelor’s Degree in Chemical Engineering from the University of Dayton and his Master’s Degree in Industrial Engineering Management from the Rochester Institute of Technology.